



Polycomb proteins work in multimeric complexes termed
polycomb repressive complexes (PRCs) to regulate the expression
of numerous developmental genes that control cell proliferation
and stem cell identity, as well as genomic imprinting and X-
chromosome inactivation, and are involved, for example, in cancer
development (Lee et al., 2006; Sparmann and van Lohuizen 2006;
Schuettengruber et al., 2007). Suz12, Eed and Ezh2 are polycomb
proteins that combine in PRC2 to silence genes (Cao et al., 2002).
In the mouse, Suz12 expression starts with a peak during
gastrulation [embryonic day (E)5.5 to E8.5]. This early expression
is essential for survival, since Suz12 knockout mice die at
gastrulation (as do Eed–/– and Ezh2–/– embryos) (Faust et al., 1998;
O’Carroll et al., 2001; Pasini et al., 2004). We detected a second
period of intense expression in several organs, including the brain,
where expression continues unabated through development and
into the adult (Fig. 1A,B). At midgestation, Suz12 was expressed
in a posterior-to-anterior gradient in the primordium of the
cerebral cortex, as well as in the tectum, hindbrain, eye primordium,
somites, first branchial arch, nasal cavity, kidney, lung, liver and
pancreas (Fig. 1C-K,O,P). Later, Suz12 transcripts appeared in the
cerebellum and hippocampus (Fig. 1L-N). We also found transcripts
of Ezh2 and Eed colocalizing with Suz12 in the developing cortex,
tectum, nasal epithelia, liver and kidney (Fig. 1Q,R), suggesting a
role for PRC2 in the development of these organs.
The role of the late peak of expression has not yet been addressed.
However, Drosophila mutants that are heterozygous for Su(z)12
show major morphological alterations, including homeotic
transformations (Birve et al., 2001). Therefore, in order to
investigate the role of Suz12 in mouse development beyond
gastrulation, we decided to generate a Suz12-deficient mouse line
(Fig. 2A,B). The homozygous knockout animals showed an early
lethal phenotype, as reported previously (Pasini et al., 2004). The
heterozygotes, however, survived and reproduced, although they
showed a range of central nervous system (CNS) abnormalities,
which were not gender related (Fig. 2C-D’’). The consistent
increases and decreases in size of specific brain regions were
particularly intriguing. In contrast to the anterior cortex (A-CTX)
and other normal-sized telencephalic regions, such as the caudate-
putamen and hippocampus, the posterior cortex (P-CTX) was
smaller in Suz12+/– mice than in wild-type animals (cortical
heterometry) (Fig. 2C-G; supplementary material Fig. S1). This
cortical heterometry correlated well with the caudo-rostral gradient
of Suz12 expression (Fig. 1D,E,P).
We then examined the expression of two marker genes that are
expressed specifically in the P-CTX during development, Id2 and
COUP-TF1 (also known as Nr2f1) (Armentano et al., 2006; Lasorella
et al., 2006). Both of these genes showed shortened domains of
expression in the heterozygous mutants, indicating that the cortical
reduction in size affects specifically the P-CTX (Fig. 2H-K).
By contrast, there was a consistent increase in the size of the
midbrain tectum of heterozygous animals, where both the superior
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and inferior colliculi (SC and IC, respectively) were enlarged
significantly (Fig. 2E-G; supplementary material Fig. S1). These
phenotypical traits co-segregated so that the individuals with the
largest reduction in the size of the P-CTX showed, at the same
time, the largest increase in IC and SC surface area. Over 60% of
the mutants measured had values that were outside the wild-type
range (supplementary material Fig. S1). The overall changes in the
P-CTX, IC and SC were statistically significant (Fig. 2G).
The enlargement of the IC and SC produced a ‘beaked tectum’
(Fig. 3A,B), which, in the most pronounced cases, caused dramatic
cerebellar herniation through the foramen magnum and a
secondary hydrocephalus (Fig. 3C,D). Magnetic resonance imaging
(MRI) of living Suz12 heterozygotes (Fig. 3E-H) showed herniation
of the cerebellar paraflocculus (corresponding to the human
cerebellar tonsils) into the foramen magnum (yellow arrowhead in
Fig. 3F,G), with a crowded posterior fossa (white arrowheads in
Fig. 3F,G).
Next, we asked what mechanism could produce the alterations
in size that we found in the Suz12 heterozygote brain. The decrease
in cortex size or increase in tectum size could be attributed to a
dysregulation of cell proliferation. Indeed, bromodeoxyuridine
(BrdU)-labeling of brains in heterozygous animals showed strongly
reduced proliferation in the P-CTX (Fig. 3I) (apoptosis, as detected
by TUNEL, was unchanged; data not shown) and increased
proliferation in the tectum (Fig. 3I). Since the role of the PRC is to
maintain transcriptional repression, the defects observed in Suz12
Fig. 1. Expression of Suz12 in mouse development.
(A) Detection of Suz12 expression through mouse embryo
development by northern blotting. Stages E4.5-E6.5 include extra-
embryonic tissues and maternal uterus; stages E7.5-E9.5 include
embryo and extra-embryonic tissues. There are two peaks of Suz12
expression, including one at the very early stages of development.
(B) The Suz12 transcript remains expressed in mouse brain up to
older ages, as shown by northern blotting. (C-K) Expression of
Suz12 in the mouse embryo. β-galactosidase (β-gal) staining on
whole-mount Suz12+/– mouse embryos at E10.5 (F) and E11.5 (G)
shows strong expression in the developing first branchial arch (br)
and liver (li). In situ hybridization (ISH) of Suz12 on coronal (C) and
sagittal (D,E,H,J,P) sections at E12.5 (C,D,H,J) and at E14.5 (E,P)
correlates with the β-gal staining on whole-mount Suz12+/– mouse
embryos at E12.5 (I) and E18.5 (K), and with β-gal ISH of Suz12+/–
mouse embryos at E14.5 (O). The Suz12 transcript shows a
posterior (p)-to-anterior (a) gradient of expression in the
primordium of the cerebral cortex (D,E,I,O,P), with no expression in
the cortical hem (hem) (C-E), and expression in the tectal
neuroepithelium (tc) (J,K), eye primordium (H,I), nasal epithelium
(ne), kidney (ki), lung (lu) and pancreas (pa) (O,P). (L-N) β-gal ISH (L)
and X-gal reaction (M,N) of Suz12+/– mouse embryos at P9 reveals
Suz12 expression in the external granular layer (egl) of the
cerebellum, as well as in the Purkinje cell layer (pcl) (L), which
represents the only expression in the adult cerebellum (M). Suz12
is also expressed in the hippocampus, with enrichment in the
adult CA2 (N). (Q,R) Transcripts of Ezh2 (Q) and Eed (R), two other
PRC2 partners, show an expression pattern similar to Suz12. Bars,
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heterozygous mice could have resulted from the inappropriate
expression of genes involved in neural stem cell proliferation. Some
targets of SUZ12 in human embryonic stem cells have recently been
mapped by chromatin immunoprecipitation on a genome-wide
scale (Lee et al., 2006). One of those targets, ZAC (also known as
PLAGL1 or LOT1), encodes a transcription factor that regulates
apoptosis and cell cycle arrest in the neuroepithelium (Varrault et
al., 2006). Intriguingly, embryonic and postnatal expression of the
murine ortholog of ZAC, Zac1, colocalized strongly with that of
Suz12 (compare Fig. 3J with Fig. 1P) (Valente and Auladell, 2001).
To verify this point, we labeled Suz12 and Zac1 with specific
antibodies on sections of E14.5 wild-type brain. The results show
Fig. 2. Suz12+/– mice show a reduced occipital cortex and enlarged tectum. (A,B) Inactivation of Suz12. (A) Schematic representation of wild-type Suz12+/+
(top) and mutated Suz12–/– (bottom) alleles. Exons are represented by black boxes. The sizes of the restriction fragments that were expected to be recognized by
the Southern probe (indicated) are shown. (B) Southern blot. (C-D’’) Suz12+/– mice show different degrees of brain reduction. A comparison between the brains of
46-day-old wild-type (C,D) and Suz12+/– (C’,C’’,D’,D’’) mice shows different degrees of reduction in the size of the P-CTX of the heterozygote (arrowheads). D-D’’
show Nissl-stained sections of C-C’’ brains. (E-G) Histological measurements show a specific reduction of the P-CTX and enlargement of the tectum in the
newborn Suz12+/– brain (discordant asymmetry). (E,F) We subdivided the cortex into two parts, anterior (A-CTX) and posterior (P-CTX), and measured them, as
well as the inferior and superior colliculus (IC and SC, respectively), hippocampus (HIPP) and caudate-putamen (CP). (G) Statistical analysis showed that Suz12+/–
brains had a reduced P-CTX, as well as an enlarged IC and SC (tectum), with no differences in the other regions. (H-K) Expression of the posterior cortical
developmental markers, Id2 (H,I) and COUP-TFI (J,K), showed shortened domains in the Suz12+/– cortex (I,K) compared with the wild-type cortex (H,J). Arrowheads
indicate the anterior boundary of the expression domain; OB, olfactory bulb (for reference). The values in G represent the mean±s.d. of measurements from
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that both proteins are colocalized in the cortical neuroepithelium
(ctx in Fig. 3K). The hem region lacks the Suz12 protein (Fig. 3K),
in agreement with our mRNA data (Fig. 1E).
Zac1 was upregulated in the Suz12 heterozygous cortex (by real-
time PCR and by ISH) (Fig. 3L-N) and tectum (Fig. 3O,P). Cultured
fibroblasts from heterozygous embryos also showed Zac1
upregulation (Fig. 3N). To verify a link between the downregulation
of Suz12 and the increase in Zac1 expression, we used small
interfering RNA (siRNA) to knockdown SUZ12 in a cell line that
is commonly used for silencing analysis of the polycomb genes
(Aoto et al., 2008), the human osteosarcoma U2Os line (U2Os-
Suz12 RNAi cells). Knocking down SUZ12 in these cells resulted
in upregulation of ZAC at the protein and mRNA levels (Fig. 3Q).
Zac1 exerts its effects by inducing the expression of Pac1 (also
known as Adcyap1r1) (Rodriguez-Henche et al., 2002), a receptor
present in the neuroepithelium. Injection of the Pac1 ligand
pituitary adenylate cyclase-activating polypeptide (PACAP) into the
developing rat cortex decreases proliferation (without increasing
apoptosis) and enhances the phosphorylation of the cAMP-
responsive element-binding protein (CREB) (Suh et al., 2001). In
agreement with this, we detected increased expression of
phosphorylated (P)-Creb in the P-CTX of heterozygous mice at
E14.5 (Fig. 3R,S), supporting our conclusion that Suz12 acts in
normal cortical development, at least in part, by regulating the
Zac1-Pac1-Creb1 pathway.
Additional phenotypical alterations that are found in the
heterozygous mice (see below) could be caused through a
dysregulation of the expression of different genes that are also
normally silenced by Suz12. Indeed, the polycomb proteins,
including Suz12, are known to regulate the spatial patterns of
homeotic box (Hox) gene expression in Drosophila (Cao and Zhang,
2004; Schuettengruber et al., 2007) and, in vertebrates, a Hox gene
Fig. 3. Beaked tectum, cerebellar herniation and
hydrocephalus, as well as altered Zac1 expression, in
Suz12+/– mice. (A,B) An enlarged beaked tectum (tc) in
Suz12+/– mice (B) results in herniation of the cerebellum
when compared with wild-type littermates (A). In the
most dramatic herniations, hydrocephalus (HYD) was
observed (C,D), including severe cerebellar (CB)
abnormalities (D). (E-H) MRI studies of 42-day-old mice.
The comparison between sagittal views of T2-weighted
MRIs of wild-type (E,F) and Suz12+/– (G,H) mice shows how
the ventral paraflocculus (the structure that corresponds
to the cerebellar tonsils in humans) goes into the foramen
magnum in Suz12+/– mice as a consequence of cerebellar
herniation (yellow arrowhead) (F,G). At the same time, the
Suz12+/– mice have a crowded posterior fossa, with the
volumes of both the cisterna cerebellomedularis and
pontis reduced (white arrowheads) (F,G). (I) BrdU labeling
showed strongly reduced proliferation, specifically in the
P-CTX (but not the A-CTX), as well as increased
proliferation in the tectum (TC). (J-P) Zac1 is specifically
upregulated in areas of altered proliferation in the
Suz12+/– brain. Zac1 shows an expression pattern that is
very similar to Suz12, as observed by ISH on Suz12+/– mice
at E14.5 (J). Zac1 (red in K) and Suz12 (green in K)
colocalize in the cortical neuroepithelium (ctx) but not in
the hem (K). Zac1 is upregulated in the Suz12+/– cortex
(CTX) (L-N) and tectal central gray neuroepithelium (tcn)
(O,P), as revealed by ISH (J,L,M,O,P) and real-time PCR (N).
In addition, real-time PCR revealed increasing expression
of Zac1 in Suz12+/– E13.5 embryonic fibroblasts (MEF) (N).
(Q) SUZ12 knockdown in human osteosarcoma U2Os cells
resulted in upregulation of ZAC. Transfection with specific
siRNA dramatically reduced SUZ12 expression, as
confirmed by western blotting and real-time PCR (Q),
resulting in upregulation of ZAC at both the protein and
mRNA levels (Q). (R,S) Detection of P-Creb by
immunohistochemistry at E14.5 revealed an increase in
the Suz12+/– P-CTX (arrowheads). The values in I represent
the mean±s.d. of measurements on three brains; the
values in N,Q represent the mean±s.d. of three
experiments. Bars, 500 μm (A-D,F,G); 1 mm (E,H,J); 100 μm
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code controls the orderly differentiation of vertebrae (Kessel and
Gruss, 1990). The most seriously affected of our heterozygous mice
showed a protuberated back (white arrowhead in Fig. 4A) and
varying degrees of spina bifida (Fig. 4E-G). These mutants
subsequently developed paraplegia (yellow arrowhead in Fig. 4A).
Suz12 is indeed expressed in the early neural tube (Fig. 4B-D).
Diastematomyelia, a vertical splitting of the spinal cord by a bony,
fibrous or cartilaginous septum (Parmar et al., 2003), was also
observed in lumbar L3-L4 vertebrae (Fig. 4H), the development of
which is controlled by Hoxd9 (Burke et al., 1995). Consistently, it
has been shown that SUZ12 binds to the HOXD9 promoter region
in human embryonic stem cells (Lee et al., 2006). Finally, some of
the Suz12 heterozygotes showed hippocampal morphological
alterations (Fig. 4I,J), as well as partial agenesis of the corpus
callosum (arrows in Fig. 4K,L). We also observed a loss of gray
matter in a gradient matching the posterior-to-anterior gradient
of Suz12 expression (see above), together with layer disorganization
in the P-CTX (Fig. 4K,L).
The morphological CNS alterations show incomplete penetrance
and variable expressivity in the heterozygous mice, and are also
found in varying degrees of severity in human patients with neural
tube defects and congenital brain malformations (Adeloye, 1976).
These severely disabling and, as a group, rather common
pathologies represent a continuum of disorders with multifactorial
etiology. One of the sub-phenotypes is Chiari malformation (CM),
which typically shows herniation of the cerebellar tonsils through
the foramen magnum with secondary hydrocephalus. Additional
symptoms may include diastematomyelia (Parmar et al., 2003);
secondary paralysis of the legs (Stevenson, 2004); abnormal gyral
pattern and dysplasia in occipital regions (Stevenson, 2004); and
partial agenesis of the corpus callosum. Thus, this syndrome shows
partial overlap with symptoms in some of the haploinsufficient
Suz12 mice, making a causative role of SUZ12 in human CNS
malformations an attractive hypothesis. However, it has to be noted
that none of these clinically defined disease entities follows a
monogenic mode of inheritance in humans, making it difficult to
obtain definite proof that SUZ12 or other genes of the polycomb
complex have a causative genetic involvement in disease
pathophysiology. Moreover, the Chiari-like phenotype in our mice
seems to be the result of the gross enlargement of the tectum, which
has not been described as a characteristic primary alteration in CM
or other clinically defined human CNS malformation syndromes,
leaving the comparability of phenotypes unclear. Nevertheless, a
direct or indirect involvement of polycomb-mediated epigenetic
changes in CNS malformations still seems attractive, particularly
because of the proven association between neural tube defects and
folate-dependent methylation pathways (see overview in Kibar et
al., 2007).
Additional evidence supporting a role for SUZ12 in human CNS
malformations may come from clinical and genetic studies on
neurofibromatosis type 1 (NF1), an autosomal dominant
phakomatosis affecting 1 in 3500 individuals, which is caused by
a heterozygous mutation in the tumor suppressor gene NF1
(Venturin et al., 2004). In addition to the characteristic tumor
predisposition and cutaneous symptoms, some NF1 patients do
also show severe mental retardation and brain malformations,
including disturbances of cortical development (Balestri et al.,
2003). The majority of NF1 cases are caused by point mutations
in the NF1 gene. However, 5-10% of cases show a larger genomic
deletion (Venturin et al., 2004), comprising the SUZ12 and around
12 additional genes, typically resulting in a more severe phenotype.
This aggravated form of the disease is probably because of the
haploinsufficiency of one or more of the additionally deleted genes,
including SUZ12. Moreover, some NF1 patients have been found
to show a CM (Tubbs et al., 2004), although a possible link to the
type of underlying mutation has not been investigated in this study.
By contrast, there is a small study that describes five independent
NF1 patients with microdeletions, all of whom show severe
developmental impairment and three of whom have structural brain
anomalies (including one patient with a CM and hydrocephalus,
and another with dysgenesis of the corpus callosum) (Korf et al.,
1999). These studies would be compatible with the hypothesis that
haploinsufficiency of SUZ12 may be involved in the development
of the more severe phenotype of NF1 microdeletion patients and
possibly in the development of diverse brain malformations or, more
generally, brain malfunction.
Epigenetic alterations are, on the one hand, essential for proper
development but, on the other hand and in the case of
dysregulation, they are increasingly being linked to a variety of
human diseases (Feinberg, 2007). For example, the involvement of
alterations in polycomb silencing in the pathogenesis of cancer is
an active area of research (Tan et al., 2007). Moreover, our results
are the first to indicate that a genetically induced alteration of
epigenetic transcriptional control mechanisms can underlie
Fig. 4. Spina bifida, diastematomyelia and callosal alterations in Suz12+/–
mice. (A) In the most impaired cases, Suz12+/– mice showed a protuberated
back (white arrowhead) and paraplegia of the posterior legs (yellow
arrowhead). (B-D) Suz12 expression in the neural tube (NT) at E8.5 (B), E9.5 (C)
and E10.5 (D). (E-H) Malformations observed in the vertebral column of
Suz12+/– mice. Diverse degrees of spina bifida (black arrows) were observed in
heterozygous mice (F,G) in contrast to wild-type mice (E). In addition,
diastematomyelia (H) was also found, caused by bony septa in lumbar L3-L4
vertebrae (white arrowheads). (I-L) Other alterations observed in the brain
were deformations of the hippocampal cortex (I,J), partial agenesis of the
corpus callosum (black arrows) (K,L), and loss of the gray matter in a gradient
(K,L; see also Fig. 3C) that follows the posterior-to-anterior Suz12 expression
gradient (Fig. 1D,E), with disorganization of cortical layers in the P-CTX of 24-
day-old Suz12+/– mice compared with wild-type brains (K,L). Bars, 500 μm
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congenital malformations of the brain and spinal cord, which
represent a diverse group of rather common and severely disabling
human disorders of the CNS.
METHODS
Suz12 mutant mice
Using a genomic clone containing Suz12 from mouse library PAC-
RPCI-21 (RPCIP711PP78, German Resource Center for Genomics),
we targeted exon 12 with lacZ and the PGK-neomycin cassette (Fig.
2A), and then generated Suz12 mutant mice as described previously
(Nagy et al., 2003). Animals were handled according to European
and German law. PCR primers for wild-type (0.35 kb) and mutant
(0.30 kb) alleles: P1, 5-GCCTGAAGAACGAGATCA-3; P2, 5-
CCAGGTCATCTTGTGGAG-3; P3, 5-TGGAGCTG GA GT -
TACCTG-3. Northern blot probe: nucleotides 3163-3937 of
GenBank ID BC064461 (Suz12).
Antibodies
Primary antidobies: anti-SUZ12 (Upstate), anti-BrdU (Dako), anti-
phospho-CREB (Upstate), anti-β-tubulin (Santa Cruz), anti-Zac1
(Santa Cruz). Secondary antibodies: biotinylated universal anti-
mouse/rabbit IgG (ABC) and HRP-conjugated anti-rabbit IgG
(Amersham).
ISH probes
IMAGE consortium CloneID (Lennon et al., 1996) and GenBank
Accession ID for ISH probes: Suz12, IRAKp961B0154Q2
(BC064461, nucleotides 3163-4448); Ezh2, IRAKp961I0810Q2
(BC016391, 1576-2595). For Zac1, Eed, LacZ and COUP-TFI, we
amplified probes from E14.5 mouse brain cDNA, covering
nucleotides: 1838-2636 of AK087432 (Zac1), 529-1531 of
AK077664 (Eed), 324-897 of U89671 (LacZ), and 621-1413 of
U07625 (COUP-TFI). For Id2, RIKEN clone 2810464O09 was used
(Kawai et al., 2001) (http://genome.gsc.riken.go.jp/).
MRI
T2-weighted images [2D fast spin-echo (FSE), repetition time
(TR)=7 seconds, effective echo time (TE)=42.7 milliseconds, 8
echos, 50 contiguous slices] were obtained in sagittal and axial
planes, at a magnetic field strength of 9.4 Tesla (Bruker Biospin
GmbH, Germany), at a spatial resolution of 100100250 μm3.
Other methods
Brain areas were measured with Scion Image software (Scion
Corporation). The real-time PCR primers for Suz12 were 5-
CTTCCCCTGCAAACGAAG-3 and 5-CCCCTGAG AC AC -
TATCTG-3. The RNAi SUZ12-specific sequence was as described
(Pasini et al., 2004). For statistics, Student’s t-test was used; P≤0.05
was considered significant.
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Suz12, mice with only one copy of Suz12 have brain and neural tube defects.
Some of the Suz12 heterozygotes show cerebellar herniation and an enlarged
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developmental brain abnormalities such as CMs can result from altered
















    
   D
M
M
Feinberg, A. P. (2007). Phenotypic plasticity and the epigenetics of human disease.
Nature 447, 433-440.
Kawai, J., Shinagawa, A., Shibata, K., Yoshino, M., Itoh, M., Ishii, Y., Arakawa, T.,
Hara, A., Fukunishi, Y., Konno, H. et al. (2001). Functional annotation of a full-
length mouse cDNA collection. Nature 409, 685-690.
Kessel, M. and Gruss, P. (1990). Murine developmental control genes. Science 249,
374-379.
Kibar, Z., Capra, V. and Gros, P. (2007). Toward understanding the genetic basis of
neural tube defects. Clin. Genet. 71, 295-310.
Korf, B. R., Schneider, G. E. and Poussaint, T. Y. (1999). Structural anomalies revealed
by neuroimaging studies in the brains of patients with neurofibromatosis type 1 and
large deletions. Genet. Med. 1, 136-140.
Lasorella, A., Stegmuller, J., Guardavaccaro, D., Liu, G., Carro, M. S., Rothschild, G.,
de la Torre-Ubieta, L., Pagano, M., Bonni, A. and Iavarone, A. (2006). Degradation
of Id2 by the anaphase-promoting complex couples cell cycle exit and axonal
growth. Nature 442, 471-474.
Lee, T. I., Jenner, R. G., Boyer, L. A., Guenther, M. G., Levine, S., Kumar, R. M.,
Chevalier, B., Johnstone, S. E., Cole, M. F., Isono, K. et al. (2006). Control of
developmental regulators by Polycomb in human embryonic stem cells. Cell 125,
301-313.
Lennon, G., Auffray, C., Polymeropoulos, M. and Soares, M. B. (1996). The I.M.A.G.E.
Consortium: an integrated molecular analysis of genomes and their expression.
Genomics 33, 151-152.
Nagy, A., Gersenstein, M. and Vintersten, K. (2003). Manipulating The Mouse Embryo:
A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.
O’Carroll, D., Erhardt, S., Pagani, M., Barton, S. C., Surani, M. A. and Jenuwein, T.
(2001). The polycomb-group gene Ezh2 is required for early mouse development.
Mol. Cell. Biol. 21, 4330-4336.
Parmar, H., Patkar, D., Shah, J. and Maheshwari, M. (2003). Diastematomyelia with
terminal lipomyelocystocele arising from one hemicord: case report. Clin. Imaging
27, 41-43.
Pasini, D., Bracken, A. P., Jensen, M. R., Lazzerini Denchi, E. and Helin, K. (2004).
Suz12 is essential for mouse development and for EZH2 histone methyltransferase
activity. EMBO J. 23, 4061-4071.
Rodriguez-Henche, N., Jamen, F., Leroy, C., Bockaert, J. and Brabet, P. (2002).
Transcription of the mouse PAC1 receptor gene: cell-specific expression and
regulation by Zac1. Biochim. Biophys. Acta 1576, 157-162.
Schuettengruber, B., Chourrout, D., Vervoort, M., Leblanc, B. and Cavalli, G. (2007).
Genome regulation by polycomb and trithorax proteins. Cell 128, 735-745.
Sparmann, A. and van Lohuizen, M. (2006). Polycomb silencers control cell fate,
development and cancer. Nat. Rev. Cancer 6, 846-856.
Stevenson, K. L. (2004). Chiari Type II malformation: past, present, and future.
Neurosurg. Focus 16, E5.
Suh, J., Lu, N., Nicot, A., Tatsuno, I. and DiCicco-Bloom, E. (2001). PACAP is an anti-
mitogenic signal in developing cerebral cortex. Nat. Neurosci. 4, 123-124.
Tan, J., Yang, X., Zhuang, L., Jiang, X., Chen, W., Lee, P. L., Karuturi, R. K., Tan, P. B.,
Liu, E. T. and Yu, Q. (2007). Pharmacologic disruption of Polycomb-repressive
complex 2-mediated gene repression selectively induces apoptosis in cancer cells.
Genes Dev. 21, 1050-1063.
Tubbs, R. S., Rutledge, S. L., Kosentka, A., Bartolucci, A. A. and Oakes, W. J. (2004).
Chiari I malformation and neurofibromatosis type 1. Pediatr. Neurol. 30, 278-280.
Valente, T. and Auladell, C. (2001). Expression pattern of Zac1 mouse gene, a new
zinc-finger protein that regulates apoptosis and cellular cycle arrest, in both adult
brain and along development. Mech. Dev. 108, 207-211.
Varrault, A., Gueydan, C., Delalbre, A., Bellmann, A., Houssami, S., Aknin, C.,
Severac, D., Chotard, L., Kahli, M., Le Digarcher, A. et al. (2006). Zac1 regulates an
imprinted gene network critically involved in the control of embryonic growth. Dev.
Cell 11, 711-722.
Venturin, M., Guarnieri, P., Natacci, F., Stabile, M., Tenconi, R., Clementi, M.,
Hernandez, C., Thompson, P., Upadhyaya, M., Larizza, L. et al. (2004). Mental
retardation and cardiovascular malformations in NF1 microdeleted patients point to
candidate genes in 17q11.2. J. Med. Genet. 41, 35-41.
















    
   D
M
M
